TREATMENT
Benefits of early intensive glucose control in preventing diabetes-related complications were sustained for up to 10 years
| The first 150 words of the full text of this article appear below. |
R R Holman
Dr R R Holman, Churchill Hospital, Oxford, UK; rury.holman@dtu.ox.ac.uk
In patients with type 2 diabetes, do the benefits of early intensive glucose control in preventing diabetes-related complications continue after the intervention is stopped?
Design: randomised controlled trial (UK Prospective Diabetes Study [UKPDS]).
Allocation: {concealed}.*
Blinding: blinded (outcome adjudication committee).
Follow-up period: median 9 years after the end of the trial, 17 years total.
Setting: 23 centres in the UK.
Patients: 4209 patients 25–65 years of age {mean age 53 y, 60% men}* who had newly diagnosed type 2 diabetes and fasting plasma glucose concentrations >6.0 mmol/l (108 mg/dl) and <15.0 mmol/l (270 mg/dl) after 3 months of dietary therapy. Exclusion criteria included ketonuria, elevated serum creatinine, recent myocardial infarction, angina, heart failure, and >1 major vascular event.
Intervention:
intensive glucose control with a sulfonylurea or insulin (n = 2729) or conventional therapy with diet (n = 1138).
School of Nursing, McMaster University, Hamilton, Ontario, Canada
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
